Recent studies into retatruptide peptide reveal promising outlook for managing obesity and type diabetes mellitus. The compound, a dual agonist of GLP-1 receptor and glucose-dependent insulinotropic polypeptide, looks to present enhanced weight loss and blood sugar control in contrast to existing